You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient characteristics

From: Evaluation of intravenous voriconazole in patients with compromised renal function

Parameter Voriconazole Caspofungin Fluconazole     p-value for overall difference
n (%) 19 (14.8) 55 (43.0) 54 (42.2)  
Age, Mean (SD) 61.7 (13.9) 63.9 (13.9) 63.7 (14.7) 0.83
Male, n (%) 10 (52.6) 34 (61.8) 20 (37.0) 0.03
White, n (%) 17 (89.5) 43 (78.2) 49 (90.7) 0.63
Length of treatment (days)     
 Mean (SD) 8.1 (6.3) 8.6 (5.3) 9.8 (9.8) 0.62
 Median (IQR) 6.0 (4–12) 7.0 (5–11) 8.0 (5–11) 0.53
 Min, Max 2, 29 2, 27 2, 74 NS
Comorbidities: Diabetes mellitus, hypertension or nephropathy, n (%) 11 (57.9) 46 (83.6) 43 (79.6) 0.06
Underlying condition, n (%)     0.001
 Cancer 12 (63)* 7 (13) 13 (24)  
 HIV 0 0 1  
 ICU 15 (79) 31 (56) 26 (48)  
 Immunosuppression** 12 (63) 3 (5) 12 (22)  
 More than 1 underlying condition 12 (63) 9 (16) 16 (30)  
Concomitant nephrotoxic agent, n (%) 14 (73.7) 31 (56.4) 27 (50.0) 0.20
Underlying fungal disease, n (%)*     0.002
Candida spp. 5 (55.6) 43 (93.5) 39 (92.9)  
Aspergillus spp. 4 (44.4) 3 (6.5) 3 (7.1)  
Indication for antifungal therapy, n (%)     NS
 Prophylaxis 10 (53) 8 (15) 5 (9)  
 Empiric 0 1 (2) 5 (9)  
 Presumed or Confirmed 9 (47) 46 (84) 42 (78)  
  1. *10 patients with AML were treated with voriconazole prophylaxis.
  2. **Chemotherapy, transplant rejection prevention or treatment, ≥ 1 mg/kg prednisone.
  3. Cases were included only when an Infectious Diseases consultant determined that the isolate represented an infection rather than colonization.